The Country’s First Health Network for Clinical Whole Genomic & Transcriptomic Sequencing

CULVER CITY, Calif.–(Business Wire)–NantHealth and The Chan Soon-Shiong Institute of Molecular Medicine founder and Chairman Dr. Patrick Soon-Shiong today announced its partnership with Providence Health and Services to create the country’s first clinical genomic network for whole genomic sequencing. Together, they have installed an Illumina HiSeq X Ten sequencing system, to establish the first CLIA-approved clinical facility to drive molecular decisions for cancer patients.

NantHealth’s clinical operating system combined with a fully integrated genomic, transcriptomic analytic super computer, capable of identifying alteration spanning from DNA to RNA to protein pathways, is capable of integrating the genetic data from a tumor sample in 47 seconds and transferring the data in 18 seconds. This capability, along with the HiSeq X Ten system, will enable Providence Health Services to perform the nation’s first clinical whole genome sequencing paired with RNA-sequencing and proteomics on all newly diagnosed cancer patients (~20,000 year) to empower physicians, patients, payers and researchers to transcend the traditional barriers of today’s healthcare system.

Providence Health and Services will be the first healthcare system that will utilize the system giving the most comprehensive view of each patient’s disease available to date. The CLIA-certified clinical genomics lab will be located at NantOmics (Culver City, CA). The clinical genomics lab with the capacity for 22 HiSeq X Ten machines, will be supported by NantOmics highly scalable cloud-based super-computing and storage infrastructure capable of analyzing the genetic data from a tumor sample at speeds capable of analyzing thousands of cancer patients per month.

“Our super-computer-driven analysis represents more than just cutting edge 21st-century clinical decision support representing the next chapter in the medical community’s fight against disease,” said Dr. Soon-Shiong. “We are now able to better understand the depth and extent of analysis required to deliver more targeted, effective and efficient treatment for patients.”

“Through this partnership, we are radically improving accuracy. Doctors will have the information to meaningfully transform the lives of our patients by giving them a real chance of beating cancer,” said Dr. Rod Hochman, president and CEO of Providence.

The HiSeq X Ten is the world’s first platform to deliver population-scale whole genome sequencing, and is capable of sequencing thousands of samples annually with high-quality.

We are thrilled to partner with Providence Health and NantHealth to bring whole genome sequencing to the clinic through their deployment of our new HiSeq X Ten platform,” said Christian Henry, Chief Commercial Officer of Illumina. “Together, we are committed to improve the clinical utility of the genome.

About The Chan Soon-Shiong Institute of Molecular Medicine

A 501c(3) non-profit medical research organization focused on transforming medical practice by facilitating digital molecular diagnosis. IOMM is building a public private coalition dedicated to working with health care, academic, government, and private sector partners to enable evidence based and molecularly driven, clinical decisions.

About NantHealth

NantHealth is a transformational healthcare company converging science and technology through a single integrated clinical platform. Through the convergence of cloud-based supercomputers, intelligent sensors, machine to machine wireless interconnectivity, artificial intelligence and federated secure grid computing, NantHealth has launched the next generation advanced population health management system. The company’s platform empowers physicians, patients, payers and researchers to transcend the traditional barriers of today’s healthcare system. For more information please visit and follow Dr. Soon-Shiong on Twitter @solvehealthcare.

About NantOmics

NantOmics is a leading medical omics company dedicated to providing actionable intelligence and molecularly driven decision support for cancer patients and their providers at point of care. NantOmics is the first molecular omics company to pioneer an integrated approach which unearths the genomic and proteomic variances that initiate and drive cancer, by analyzing both normal and tumor cells from the same patient, from DNA to RNA to protein to drug. For more information please visit and follow Dr. Soon-Shiong on Twitter @solvehealthcare.

About Illumina

Illumina ( is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its applications, paving the way for molecular medicine and ultimately transforming healthcare.